LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

104.85 2.08

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

104.15

Max

105.23

Schlüsselkennzahlen

By Trading Economics

Einkommen

7.2M

-93M

Verkäufe

33M

265M

Gewinnspanne

-34.965

Angestellte

1,999

EBITDA

6.6M

-82M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+22.39% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

19. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

4.7B

14B

Vorheriger Eröffnungskurs

102.77

Vorheriger Schlusskurs

104.85

Nachrichtenstimmung

By Acuity

50%

50%

127 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Feb. 2026, 23:21 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. Feb. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. Feb. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. Feb. 2026, 23:06 UTC

Ergebnisse

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Shareholders to Receive A$5.20/Share in Cash

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. Feb. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. Feb. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. Feb. 2026, 20:48 UTC

Ergebnisse

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. Feb. 2026, 20:47 UTC

Ergebnisse

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. Feb. 2026, 20:46 UTC

Ergebnisse

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. Feb. 2026, 20:45 UTC

Ergebnisse

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. Feb. 2026, 20:43 UTC

Ergebnisse

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope Net Debt A$2.2 Million at Dec. 31

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. Feb. 2026, 20:41 UTC

Ergebnisse

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. Feb. 2026, 20:39 UTC

Ergebnisse

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

22.39% Vorteil

12-Monats-Prognose

Durchschnitt 128.33 USD  22.39%

Hoch 175 USD

Tief 105 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

127 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat